<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377868</url>
  </required_header>
  <id_info>
    <org_study_id>IM.AS.01</org_study_id>
    <nct_id>NCT03377868</nct_id>
  </id_info>
  <brief_title>Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, devastating, neurodegenerative disease
      characterized by the loss of cortical, brain stem, and spinal motor neurons. Visual evoked
      potentials studies in patients with ALS suggest visual pathway involvement. Optic coherence
      tomography (OCT) is a non-invasive cross-sectional imaging modality measuring the optical
      reflections in biological tissues. The main objective of this observational cohort study is
      to explore the correlation between changes on OCT retinal parameters and and clinical
      disability as measured by the ALS Functional Rating Scale (ALS-FRS-r) in patients with ALS at
      baseline, 3 and 6 months. A secondary objective is to explore the correlation between changes
      in retinal OCT parameters and pulmonary function tests (FVC and FEV1) in this cohort of
      patients with ALS. A parallel cohort of healthy age and sex matched subjects will participate
      as controls to obtain reference values of their retinal layers' thickness at baseline, 3 and
      6 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2018</start_date>
  <completion_date type="Anticipated">September 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Observational study of a cohort of patients with amyotrophic lateral sclerosis compared to a parallel cohort of healthy age and sex matched subjects</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in retinal layer thickness parameters over 3 and 6 months in ALS patients</measure>
    <time_frame>6 months</time_frame>
    <description>Observing the change in retinal layers thickness parameters in micrometers in ALS patients from baseline to 3 and 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in retinal layer thickness parameters over 3 and 6 months between ALS patients and their healthy controls</measure>
    <time_frame>6 month</time_frame>
    <description>Comparison of changes in retinal layer thickness parameters over 3 and 6 months between ALS patients and their healthy controls in micrometers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between changes in retinal layers thickness and ALS-FRS scores in patients with ALS</measure>
    <time_frame>6 month</time_frame>
    <description>Correlation between changes in retinal layers thickness in micrometers and ALS-FRS scores in ALS patients over 3 and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between changes in retinal layers thickness and Pulmonary function test parameters in ALS patients over 3 and 6 months</measure>
    <time_frame>6 month</time_frame>
    <description>Correlation between changes in retinal layers thickness parameters in micrometers and changes in FEV1 in liters and FVC in liters on pulmonary function testing in patients with ALS over 3 and 6 month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients with Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients diagnosed with amyotrophic lateral sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Parallel cohort of healthy age and sex matched subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optic coherence tomography</intervention_name>
    <description>Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.</description>
    <arm_group_label>Patients with Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulmonary function test</intervention_name>
    <description>Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.</description>
    <arm_group_label>Patients with Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ALS according to the El Escorial criteria.

          -  Age 18 years to 80 years old

          -  Disease duration less than 36 months

          -  Patients logistically able to attend and be evaluated at baseline, 3 and 6 months

        Exclusion Criteria:

          -  Patients with diabetes mellitus

          -  Patients with glaucoma, refractive errors of ± 6 diopters or more, or other
             ophthalmologic disorders such as media opacities that could interfere with retinal OCT
             assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Achraf Makki, MD</last_name>
    <phone>+9611350000</phone>
    <phone_ext>7359</phone_ext>
    <email>am132@aub.edu.lb</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elia Malek, MD</last_name>
    <email>em26@aub.edu.lb</email>
  </overall_contact_backup>
  <reference>
    <citation>Calvo AC, Manzano R, Mendonça DM, Muñoz MJ, Zaragoza P, Osta R. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int. 2014;2014:925101. doi: 10.1155/2014/925101. Epub 2014 Aug 3. Review.</citation>
    <PMID>25157374</PMID>
  </reference>
  <reference>
    <citation>Grosskreutz J, Kaufmann J, Frädrich J, Dengler R, Heinze HJ, Peschel T. Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. BMC Neurol. 2006 Apr 25;6:17.</citation>
    <PMID>16638121</PMID>
  </reference>
  <reference>
    <citation>Hammad M, Silva A, Glass J, Sladky JT, Benatar M. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology. 2007 Dec 11;69(24):2236-42.</citation>
    <PMID>18071143</PMID>
  </reference>
  <reference>
    <citation>Radtke RA, Erwin A, Erwin CW. Abnormal sensory evoked potentials in amyotrophic lateral sclerosis. Neurology. 1986 Jun;36(6):796-801.</citation>
    <PMID>3703285</PMID>
  </reference>
  <reference>
    <citation>Münte TF, Tröger MC, Nusser I, Wieringa BM, Johannes S, Matzke M, Dengler R. Alteration of early components of the visual evoked potential in amyotrophic lateral sclerosis. J Neurol. 1998 Apr;245(4):206-10.</citation>
    <PMID>9591221</PMID>
  </reference>
  <reference>
    <citation>Moss HE, McCluskey L, Elman L, Hoskins K, Talman L, Grossman M, Balcer LJ, Galetta SL, Liu GT. Cross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population. J Neurol Sci. 2012 Mar 15;314(1-2):97-101. doi: 10.1016/j.jns.2011.10.016. Epub 2011 Dec 21.</citation>
    <PMID>22192877</PMID>
  </reference>
  <reference>
    <citation>Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al. Optical coherence tomography. Science. 1991 Nov 22;254(5035):1178-81.</citation>
    <PMID>1957169</PMID>
  </reference>
  <reference>
    <citation>Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS, Izatt JA, Swanson EA, Fujimoto JG. Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995 Feb;102(2):217-29.</citation>
    <PMID>7862410</PMID>
  </reference>
  <reference>
    <citation>Jiménez B, Ascaso FJ, Cristóbal JA, López del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord. 2014 Jan;29(1):68-74. doi: 10.1002/mds.25747. Epub 2013 Nov 14.</citation>
    <PMID>24458320</PMID>
  </reference>
  <reference>
    <citation>Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabárbara J, Pascual LF, Lobo A, Cristóbal JA. Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J Neurol. 2014 Aug;261(8):1522-30. doi: 10.1007/s00415-014-7374-z. Epub 2014 May 21.</citation>
    <PMID>24846203</PMID>
  </reference>
  <reference>
    <citation>Bertuzzi F, Suzani M, Tagliabue E, Cavaletti G, Angeli R, Balgera R, Rulli E, Ferrarese C, Miglior S. Diagnostic validity of optic disc and retinal nerve fiber layer evaluations in detecting structural changes after optic neuritis. Ophthalmology. 2010 Jun;117(6):1256-1264.e1. doi: 10.1016/j.ophtha.2010.02.024. Epub 2010 Apr 9.</citation>
    <PMID>20381872</PMID>
  </reference>
  <reference>
    <citation>Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F; GJCF-ICC&amp;BR. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015 May;21(6):678-88. doi: 10.1177/1352458514567216. Epub 2015 Feb 6. Review.</citation>
    <PMID>25662342</PMID>
  </reference>
  <reference>
    <citation>Roth NM, Saidha S, Zimmermann H, Brandt AU, Oberwahrenbrock T, Maragakis NJ, Tumani H, Ludolph AC, Meyer T, Calabresi PA, Paul F. Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. Eur J Neurol. 2013 Aug;20(8):1170-6. doi: 10.1111/ene.12146. Epub 2013 Apr 14.</citation>
    <PMID>23582075</PMID>
  </reference>
  <reference>
    <citation>Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O. Subtle retinal pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014 Apr;1(4):290-7. doi: 10.1002/acn3.46. Epub 2014 Mar 11.</citation>
    <PMID>25590041</PMID>
  </reference>
  <reference>
    <citation>Simonett JM, Huang R, Siddique N, Farsiu S, Siddique T, Volpe NJ, Fawzi AA. Macular sub-layer thinning and association with pulmonary function tests in Amyotrophic Lateral Sclerosis. Sci Rep. 2016 Jul 7;6:29187. doi: 10.1038/srep29187.</citation>
    <PMID>27383525</PMID>
  </reference>
  <reference>
    <citation>Saidha S, Al-Louzi O, Ratchford JN, Bhargava P, Oh J, Newsome SD, Prince JL, Pham D, Roy S, van Zijl P, Balcer LJ, Frohman EM, Reich DS, Crainiceanu C, Calabresi PA. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol. 2015 Nov;78(5):801-13. doi: 10.1002/ana.24487. Epub 2015 Oct 1.</citation>
    <PMID>26190464</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 16, 2017</last_update_submitted>
  <last_update_submitted_qc>December 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Achraf Makki</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

